MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection

Abdel-Rahman N. Zekri1*, Enas Reda El-Sisi1, Amira Salah El-Din Youssef1, Mahmoud M. Kamel4, Auhood Nassar1, Ola Sayed Ahmed1,7, Mohamed El Kassas3, Ahmed Barakat Barakat6, Alaa Ismail Abd El-Motaleb5, Abeer A. Bahnassy6

1 Molecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt, 2 Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt, 3 Endemic Medicine Department, Faculty of Medicine, Helwan University, Helwan, Egypt, 4 Microbiology Department, Faculty of Science, Ain Shams University, Cairo, Egypt, 5 Surgery Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 6 Tissue Culture and Cytogenetics Unit, Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt, 7 Photobiology and Molecular Biology Department, Laser Institute for Research and Applications (LIRA), Beni-Suef University, Beni Suef, Egypt

* ncizekri@yahoo.com

Abstract

Aim

Molecular characterization of the CD133+ stem cells associated with hepatocarciogenesis through identifying the expression patterns of specific microRNAs (miRNAs).

Methods

We investigated the expression pattern of 13 miRNAs in purified CD133+ cells separated from the peripheral blood of healthy volunteers, chronic hepatitis C (CHC), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) patients along with bone marrow samples from the healthy volunteers and the LC patients using custom miScript miRNA PCR array.

Results

The differential expression of the 13 studied miRNAs in CD133+ cells separated from the HCC patients’ peripheral blood compared to the controls revealed that miR-602, miR-181b, miR-101, miR-122, miR-192, miR-125a-5p, and miR-221 were significantly up regulated (fold change = 1.8, 1.7, 2, 5.4, 1.6, 2.9 & 1.5 P value = 0.039, 0.0019, 0.0013, 0.0370, 0.00024, 0.000044 & 0.000007 respectively). As for the HCC group compared to the CHC group; miR-602, miR-122, miR-181b, miR-125a-5p, and miR-192 were significantly up regulated (fold change = 13, 3.1, 2.8, 1.6 & 1.56, P value = 0.01, 0.001, 0.000004, 0.002 & 0.007 respectively). Upon comparing the HCC group to the LC group; miR-199a-3p, miR-192, miR-181b, miR-224, miR-125a-5p, and miR-885-5p were significantly up regulated (fold change = 5, 6.7, 2.3, 2.5, 4.2 & 39.5 P value = 0.001025, 0.000024, 0.000004, 0.000075 & 0.000001 respectively) whereas miR-22 was significantly down regulated (fold change = 0.57 P value = 0.0002). Only, miR-192, miR-122, miR-181b...
and miR-125a-5p were significant common miRNAs in CD133+ cells of the HCC group compared to the other non-malignant groups.

**Conclusion**

We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD133+ cells associated with different stages of hepatocarcinogenesis. This panel may aid in developing a new target therapy specific for those CD133+ cells.

**Introduction**

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the second leading cause of the cancer-related death in the world. Also, it ranks as the fifth and seventh common cancer in men and women respectively [1]. Egypt is one of the countries who has the highest prevalence of hepatitis C virus (HCV) worldwide estimated by (21.9%) among adults in 1995–1996 [2].

CD133+ is a transmembrane glycoprotein that known as an important cell surface marker of the putative normal liver stem cells “oval cells” as well as cancer stem cells (CSCs) [3–6]. In line with this, the increased expression of CD133+ was found to be correlated with advanced stages of HCC [7,8]. A special attention is given to the naïve circulating CD133+ cells and its clinical significance in HCC prognosis. We have previously showed that circulating CD133+ cells were significantly higher in the blood samples of chronic hepatitis and HCC patients compared to the healthy controls; revealing the prognostic role of CD133+ cells in those patients [9].

MicroRNAs (miRNAs) are small, non-coding RNAs that can regulate carcinogenesis and cancer development through their complementary binding to mRNAs of oncogenes or tumor suppressors genes [10,11]. miRNAs are involved in the regulation of proliferation and self-renewal of the CSCs and they also promote the differentiation to determine the fate of stem cell [12]. Both normal stem cells (NSCs) and CSCs are regulated by miRNAs which accounts for the importance of the identifying the most common and unique miRNAs expression patterns between CSCs and NSCs.

The purpose of this study is to assess the expression patterns of 13 miRNAs in the naïve circulating CD133+ stem cells associated with different stages of hepatocarcinogenesis on top of HCV infection. Those miRNAs have been previously reported in literature to play a role in hepatocarcinogenesis machinery. Also, this study is considered as a complementary study to our previously published paper which illustrated the expression pattern of those miRNAs in the serum samples of CHC, LC and HCC patients on top of HCV infection as well as healthy controls [13, 14].

**Patients and methods**

**Study design**

This retrospective case control study was conducted on thirty subjects who attended the National Cancer Institute, Cairo University. The recruited patients were categorized into five groups; 1) six donors for bone marrow (BM) transplantation who were enrolled as control group; 2) nine chronic hepatitis C (CHC) patients; 3) six patients with liver cirrhosis (LC) and 4) nine HCC patients 5) additional 16 blood samples act as confirmatory set (8 HCC and 8 Control samples). All control subjects had normal serum alanine aminotransferase (ALT) level.
and all were seronegative for HBV and HCV antibodies. The CHC and LC patients were diagnosed by clinical examination, abdominal ultrasound, laboratory investigations and liver biopsy. The diagnosis of HCC patients was based on computed tomography (CT) and elevated AFP level and confirmed by histopathology. The criteria for inclusion were as follows: a) adult patients of both sexes who were positive for HCV antibodies (EIAgen HCV Ab (v.4) kit code: 071064, adaltis. Milano Italy) as well as HCV RT-PCR (artus HCV RT-PCR Kits CE, cat no. 4518265, QIAGEN GmbH, QIAGEN Strasse 1, D-40724 Hilden); b) newly diagnosed HCC cases without prior chemotherapy. The criteria for exclusion were as follows: a) patients with positive hepatitis B surface antigen (HBsAg) and was confirmed by PCR; b) patients who received previous treatment for HCC. The study was approved by the Institutional Review Boards (IRB) of the National Cancer Institute, Cairo University, which was in accordance with the guidelines of 2004 Declaration of Helsinki. A written informed consent was obtained from all participants prior to enrollment in the study (Organization No.IORG0003381. IRB NO. IRB00004025).

**Collection of clinical specimen**

Ten milliliters of venous peripheral blood were collected from all enrolled subjects in Cell-Save blood collection tubes (Immunicon Inc., Huntingdon Valley, PA, United States) containing a cellular preservative and EDTA. Similarly, 10 ml of heparinized BM aspirate were collected from LC patients and normal volunteers during their regular treatment regimen and follow up. Briefly, patients’ skin was cleaned with 70% ethanol at the iliac crest with a boring movement. Then, needles were passed perpendicularly into the cavity of the ileum at a point just posterior to anterior superior iliac spine or 2 cm posterior and 2 cm inferior to the anterior superior iliac spine to aspirate the BM (Salah and Klima New Delhi 110055, Delhi, India). The mononuclear cells were isolated from freshly collected peripheral blood and BM samples using RBC’s lysis buffer. Cells were washed twice using phosphate buffer saline and counted using a hemocytometer.

**CD133+ cells’ sorting**

CD133+ cells were isolated using MACS kit (Miltenyi Biotec, Germany) according to manufacturer’s instructions. The mononuclear cells were incubated for 30 min. at 4°C after labeling with 100μl CD133/1 magnetic microbeads and 100 μl FcR. Then, the cells were sorted twice using the autoMACS® separator (Miltenyi Biotec, Germany) to increase their purity. The cells were washed twice with phosphate buffered saline (pH 7.2); supplemented with 0.5% bovine serum albumin and 2mM EDTA, and centrifuged at 300 xg for 10 min at 4°C. For confirmatory set, CD133+ cells were sorted using the BD FACSCalibur™ (BD Biosciences, USA) platform that allows performing both cell analysis and cell sorting in a single bench top system.

**Flow cytometry analysis**

The sorted cells were incubated with phycoerythrin (PE)-conjugated anti-CD133/2 for 30 min at 4°C. (Miltenyi Biotec, Bergisch Gladbach, Germany). Then, they were treated with FcR blocking reagent (Miltenyi Biotec). The labeled cells were analyzed with Flowcytometer Epics® Elite Coulter system using the CELL Quest software (Becton–Dickinson Immunocytometry Systems, San Jose, CA, USA). A nonspecific isotype control was used in each sample. All antibodies were of IgG1k isotype. Results were expressed as a specific percentage of positive markers, calculated by subtracting the nonspecific fluorescence of the isotype control form the specific fluorescence of the monoclonal antibody.
RNA extraction and cDNA synthesis

Total RNA including miRNA was extracted using RNeasy mini kit (Qiagen cat. no. 217004) and QIAzol lysis reagent according to manufacturer’s instructions. The quality of the RNA was estimated using 2000/2000c nanodrop (Thermo scientific, USA). RT2 miRNA First Strand Kit (Qiagen) was used to prepare cDNA from 500 ng RNA. Reverse transcription was carried out in a final reaction volume of 20 μl that were incubated for 60 min at 37˚C followed by 5 min at 95˚C.

Quantitative real-time PCR

The relative expression levels of 13 mature miRNAs [hsa-miR-122, hsa-miR-192, hsa-miR-885-5p, hsa-miR-375, hsa-miR-224, hsa-221, hsa-miR-22, hsa-miR-101, hsa-miR-602, hsa-miR-125a-5p, hsa-miR-181b, and hsa-miR-199a-3p] in CD133 cells were performed using miScript miRNA PCR custom array (SABiosciences, custom array catalog number calh0038). For real time PCR, the reaction mixture contained 13 μl SYBR PCR master mix and 2 μl diluted cDNA (1:10) in a final volume of 25 μl for each miRNA. The amplification step was carried out for 40 cycles according to the following conditions: 95˚C for 10 minutes, 1 cycle; 95˚C for 15 seconds, 60˚C for 40 seconds, 72˚C for 30 seconds. The 13 miRNAs were compared and analyzed across multiple plates using the ΔΔCt method and normalized to snord48 (housekeeping gene).

miRNAs selection and target prediction

The selection of the miRNAs was based on a previous review of literature along with using miR2Disease database; a comprehensive resource of miRNA deregulation in various human diseases (http://www.mir2disease.org). While, miRTaBase database; the experimentally validated miRNA-target interaction database (mirtarbase.mbc.nctu.edu.tw) was used to predict downstream targets of miRNAs.

Confirmatory reverse transcription and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

CD133 cells were sorted from blood samples obtained from eight HCC patients and eight control subjects using flowcytometry with cell sorter. Total RNA was reverse transcribed for sorted CD133 cells using miScript II RT kit (Qiagen). Reactions were incubated at 37˚C for 1 hr followed by inactivation of the reaction by incubation at 95˚C for 10 min. For miRNA expression Confirmatory Real-time PCR was carried out for the four miRNAs (miRNA-122, miRNA181b, miRNA-125a-5p, miRNA-192) using primers specific for these miRNAs, Table 1, 1 μL of diluted RT product was used (equivalent to 3 ng) as template in a 10 μL PCR reaction containing 1X SYBR Green master mix (Qiagen), 200nMmiRNA specific forward primer, and 200 nM universal primer. The conditions for qRT-PCR were as follows: 95˚C for 10min, followed by 40 cycles of 95˚C for 15s and 50˚C for 30 s and 70˚C for 30 s. All the RT-qPCR reactions

Table 1. The primer sequence of the four miRNAs used for the confirmatory set.

| miRNA     | Sequence          |
|-----------|-------------------|
| hsa-miR-122 | UGGAGUGUGACAAUGG UGUUUG   |
| hsa-miR-192 | CUGACCUAUGAAUUGACAGCC   |
| hsa-miR-125a-5p | UCCCGAGACCCCUUACCUGUGA |
| hsa-miR-181b | AAACAUUCAUGCGUGGGGUGGGGU |

https://doi.org/10.1371/journal.pone.0193709.t001
were performed on 7500 fast real-time PCR system (Applied Biosystems). All samples were analysed in duplicate.

**Statistical analysis**

Data analysis was performed using the supplied software "http://www.sabiosciences.com/pcrarraydataanalysis.php"; based on Student’s t-test of the replicate \((2^\Delta \Delta Ct)\) values for each miRNA in the tested groups and the control group. P-values less than 0.05 are considered statistically significant. Fold-change values >1 imply an up-regulation while fold-change values <1 imply a down-regulation. The SPSS software package (version 15) was used to analyze the clinical data. Continuous variables were expressed as median and range while categorical variables were expressed as percentages. Comparisons between groups were analyzed by one way ANOVA for the continuous variables and by the \(\chi^2\) or Fisher’s exact test for the categorical variables whenever possible.

**Results**

**The demographic features and the clinical data of the studied groups**

The demographic and the clinical features of the different studied groups were shown in Table 2. The age differed significantly between the studied groups (P value < 0.05) with a trend for increasing ages with disease progression. However, there was no significant difference between the LC and the HCC groups regarding the age. Also, no significant difference was observed regarding the gender between the studied groups with male predominance in the groups with HCV-related liver disease except for those in the CHC group. The level of AST was significantly higher in the LC and CHC groups compared to the other groups (P value < 0.05). However, levels of total bilirubin and AST were significantly higher in the LC group compared to the other groups (P value < 0.05, 0.01 respectively). Albumin was significantly lower in the LC group compared to the other groups (P value < 0.05) whereas; AFP was significantly higher in the HCC group compared to the other groups (P value < 0.01).

**CD133+ subpopulation purity in the different studied groups**

Prior to performing the custom miScript miRNA PCR array, the purity of sorted CD133+ cells was tested in all studied groups by flowcytometry. The purity of CD133+ subpopulation ranged from 67 to 76% in the different studied groups as shown in Fig 1.

**The differential expression of miRNAs in CD133+ cells purified from the peripheral blood (PB) of the different studied groups**

Among the 13 studied miRNAs, only miR-101 was significantly up regulated (fold change = 1.69 P value = 0.016) while miR-122 was significantly down regulated (fold change = -1.74 P value = 0.0114) upon comparing CD133+ cells of the CHC group to those of the control group as shown in S1 Table and Fig 2A. Moreover, miR-22 and miR-101 were significantly up regulated (fold change = 2.4 & 2.7 P value = 0.000002 & 0.0002 respectively) whereas miR-122, miR-192, miR-885-5p, miR-224, miR-125a-5p and miR-199a-3p were significantly down regulated (fold change = 0.36, 0.25, 0.55, 0.33.0.66 & 0.03 P value = 0.000009, 0.005, 0.011, 0.015, 0.000001 & 0.03 respectively) on comparing CD133+ cells of the LC group to the control group as shown in S2 Table and Fig 2B. Furthermore, miR-122, miR-192, miR-101, miR-602, miR-125a-5p, miR-181b and miR-221 were significantly up regulated (fold change = 1.8, 1.7, 2, 5.4, 1.6, 2.9 & 1.5 P value = 0.039, 0.0019, 0.0013, 0.0370, 0.00024, 0.0000044 & 0.000007 respectively) upon comparing CD133+ cells of the HCC group to the control group as shown in S3 Table and Fig 2C.
The heat map with dendograms for the differential expression of 13 miRNAs in CD133+ cells of the three studied groups compared to the control group indicates co-regulated miRNAs across all studied groups along with multi group plot provided both a bar chart and line graph representation (with optional error bars) are shown in Fig 3.

Among the 13 studied miRNAs in CD133+ cells of the HCC group compared to the CHC group; miR-602, miR-122, miR-181b, miR-125a-5p and miR-192 were significantly up regulated (fold change = 13, 3.1, 2.8, 1.6 & 1.56; P value = 0.01, 0.001, 0.000004, 0.002 & 0.007; respectively) as shown in S4 Table and Fig 4A. On comparing CD133+ cells of the HCC group to the LC group; miR-122, miR-192, miR-885-5p, miR-224, miR-125a-5p, miR-181b and miR-199a-3p were significantly up regulated (fold change = 5, 6.7, 2.3, 3, 2.5, 4.2 & 39.5 P value = 0.001025, 0.000024, 0.000472, 0.000278, 0.000004, 0.000075 & 0.0000001 respectively) whereas miR-22 was significantly down regulated (fold change = 0.57 P value = 0.00002) as shown in S5 Table and Fig 4B. The differential expression of 13 miRNAs in CD133+ cells of the HCC group compared to the other studied groups was illustrated in Fig 4C and Fig 4D.

It has been shown that miR-122, miR-192, miR-125a-5p and miR-181b were significantly common up regulated miRNAs in CD133+ cells of the HCC group (fold change = 5, 6.7, 2.3 & 39.5, P value = 0.001025, 0.000024 & 0.0000001; respectively) up on comparing CD133+ cells of the malignant group (HCC group) to the other non-malignant groups (CHC, LC and control groups) as shown in S6 Table.

### Table 2. The clinical data of the studied groups.

|                  | Control (n = 6) | Non cirrhotic (n = 9) | Cirrhotic (n = 6) | HCC (n = 6) | P value |
|------------------|----------------|-----------------------|------------------|-------------|---------|
| **Age**          |                |                       |                  |             | <0.05   |
| Median           | 30.5 a         | 42 b                  | 56 c             | 64 c        |         |
| Range            | (26–34)        | (28–58)               | (43–63)          | (49–88)     |         |
| **Gender**       |                |                       |                  |             | 0.07    |
| Male             | 5 (83%) a      | 4 (44%) a             | 4 (67%) a        | 4 (67%) a   |         |
| Female           | 1 (17%) a      | 5 (56%) a             | 2 (33%) a        | 2 (33%) a   |         |
| **ALT**          |                |                       |                  |             | <0.05   |
| Median           | 12 a           | 47 b                  | 45 b             | 25.5 ab     |         |
| Range            | (7–22)         | (31–83)               | (34–145)         | (12.9–74)   |         |
| **AST**          |                |                       |                  |             | <0.05   |
| Median           | 15 a           | 39 b                  | 70 c             | 38.5 b      |         |
| Range            | (12–36)        | (24–64)               | (59–134)         | (35–137)    |         |
| **T.Bilirubin**  |                |                       |                  |             | <0.01   |
| Median           | 0.6 a          | 0.9 a                 | 2.78 c           | 1.35 a      |         |
| Range            | (0.5–0.9)      | (0.3–1.92)            | (1.4–6.52)       | (0.37–2)    |         |
| **Albumin**      |                |                       |                  |             | <0.05   |
| Median           | 3.5 a          | 4.6 b                 | 2.6 c            | 3.5 a       |         |
| Range            | (3.0–4.6)      | (4.0–4.9)             | (2.0–3.0)        | (2.5–4.2)   |         |
| **HCV Ab**       |                |                       |                  |             | <0.01   |
| Present          | 0 (0%) a       | 9 (100%) b            | 6 (100%) b       | 6 (100%) b  |         |
| Absent           | 6 (100%) a     | 0 (0%) b              | 0 (0%) b         | 0 (0%) b    |         |
| **AFP**          |                |                       |                  |             | <0.01   |
| Median           | 1.2 a          | 5.7 b                 | 5.8 b            | 297 c       |         |
| Range            | (0.2–3.5)      | (0.8–12.7)            | (3.6–6.0)        | (18.2–1274.7) |     |

Groups bearing different initials are significantly different. "ALT" = alanine aminotransferase, "AST" = aspartate aminotransferase, "AFP" = alpha fetoprotein, "T-Bilirubin" = total bilirubin.

https://doi.org/10.1371/journal.pone.0193709.t002
The histograms representing the differential expression of miRNAs in CD133+ cells purified from peripheral blood of all studied groups were shown in Fig 5.

The possible mechanistic role of significant overlapping miRNAs in CD133+ cells of HCC with their downstream targets as well as the relationship between miRNAs and HCV were illustrated in Table 3 and Fig 6.

The differential expression of miRNAs in CD133+ cells purified from the bone marrow (BM) of the different studied groups

The differential expression of the studied miRNAs in CD133+ cells separated from BM to those separated from PB of the control group revealed that only 3 out of 13 miRNAs were significantly up regulated; miR-122, miR-221 and miR-125a-5p (fold change = 1.4, 1.5 & 1.6 P value = 0.044, 0.000004 & 0.001312 respectively) as shown in S7 Table and Fig 7A. Furthermore, miR-885-5p, miR-224 and miR-199a-3p were significantly up regulated (fold change = 1.74, 2 & 18.2 P value = 0.048477, 0.031087&0.000091 respectively) whereas miR-22, miR-101 and miR-29b were significantly down regulated (fold change = 0.19, 0.2 & 0.28 P value = 0.000001, 0.000002 &0.003336 respectively) upon comparing CD133+ cells separated from BM to those separated from PB of the LC group as shown in S8 Table and Fig 7B. On comparing CD133+ cells separated from BM of the LC group to those separated from BM of the control group miR-122, miR-192, miR-224 miR-22 miR-101, miR-125a-5p, miR-29b and miR-199a-3p were significantly down regulated (fold change = 0.34, 0.37, 0.54, 0.41, 0.31, 0.48, 0.6, 0.27 & 0.5 P value = 0.00015, 0.000046, 0.000249, 0.000287, 0.000001, 0.000397, 0.009098, 0.000004 & 0.000051 respectively) and only miR-602 was significantly up regulated (fold change = 2.7 P value = 0.02) as shown in S9 Table and Fig 7C.

![Fig 1. The percentage of CD133+ cells in the different studied groups.](https://doi.org/10.1371/journal.pone.0193709.g001)

After sorting by autoMACS™ (Miltenyi Biotec), the percentage of CD133+ fractions ranged from 67–76%.
The histograms representing the differential expression of miRNAs in CD133+ cells purified from bone marrow of the LC and control groups were shown in Fig 8.

**Confirmatory set results**

The differential expression of the studied miRNAs in CD133+ of the HCC group compared to the control group showed up regulation of miR-181b, miR-192, miR-125a-5p and miR-122 in concordance with the our previous data Table 4, Fig 9. Moreover, there is no significant difference in the miRNA expression between both methods used for CD133+ cell sorting.
Cancer stem cells (CSCs) represent a subset of cells that exist within the tumor. They are responsible for resistance, survival and recurrence after the treatment. CD133+ has drawn significant attention as a critical liver CSC marker [15]. There is evidence that miRNAs are significantly involved in self-renewal and differentiation of CSCs [16]. They are responsible for regulating the stemness characteristics through modulation of tumor-suppressive and oncogenic pathways [17].

In this study, we aimed to differentiate between the naïve circulating CD133+ cells obtained from patients at different stages of HCV-associated liver disease and the CD133+ cells of the healthy controls at the molecular level through comparing the expression patterns of 13 miRNAs.

Our results revealed that miR-181b, miR-602, miR-101, miR-122, miR-192, miR-125a-5p, miR-221 and miR-22 were significantly up regulated up on comparing CD133+ cells of the HCC group (PB) to those of the control group (PB).
MiR-181b which belongs to miR-181s family; plays an important role in liver injury and cancer development [18]. Significant up regulation of miR-181b was in concordance with a previous report by Ji et al. who found that multiple members of the miR-181 family, including miR-181b are up-regulated in the liver CSC subset marked with EpCAM+ AFP+ [19]. Similarly, our previous study addressed that miR-181 was significantly up regulated in sera of the HCC group when compared to the LC group [14]. Moreover, Meng et al identified the differential expression of miR-181 family members in an Oct4 + CD133 + liver CSC subset. They also identified a critical role for miR-181s in Twist-driven metastasis in this Oct4 liver CSCs through targeting RAS-association domain family 1, isoform A (RASSF1A), tissue inhibitor of metalloproteinase 3 (TIMP3) and nemo-like kinase (NLK) [18]. Furthermore, miR-181s was

Fig 4. A) Volcano plot representing the differential expression of the 13 miRNAs in CD133+ cells of the HCC group (PB) versus the CHC group (PB). B) Volcano plot representing the differential expression of the 13 miRNAs in CD133+ cells of the HCC group (PB) versus the LC group (PB). C) Venn graph represented the differential expression of the 13 miRNAs in the CD133+ of HCC group (PB) in comparison with the control, CHC, and LC groups. D) Histogram showing the differential expression of the 13 miRNAs in CD133+ cells of the HCC group (PB) versus other non-malignant groups (PB).** miRNA is significant at 0.05 level while *** miRNA is significant at 0.01 level.

https://doi.org/10.1371/journal.pone.0193709.g004
found to maintain stemness by directly targeting GATA-binding protein 6 (GATA6) caudal type homeobox 2 (CDX2) and nemo-like kinase (NLK) which is a potent inhibitor of β-catenin resulting in activation of the Wnt/β-catenin pathway in EpCAM + liver CSCs [19].

Our data regarding the significant up regulation of miR-602 was in agreement with yang et al. who identified the oncogenic function of miR-602 in HCC through targeting the tumor suppressive function of RASSFIA [20].
On the other hand, miR-101 was reported to inhibit tumor aggressiveness through targeting EZH2 which is an epigenetic regulator of cell survival, proliferation, CSC phenotype and function, in various cancers including endometrial cancer [21], prostate cancer [22], and pancreatic cancer [23]. On contrary to these data, we found that miR-101 was significantly up regulated. The possible explanation is that individual miRNA may act as oncomir or tumor suppressor according to its organ specificity.

Besides, miR-122 and miR-192 are the most two abundantly expressed miRNAs in the human liver [24]. miR-122 represents 70% of the total miRNAs in the normal liver [25,26]. In the primary HCC tissues as well as hepatoma cell lines, miR-122 was found to be down-regulated conceiving its role as a tumor-suppressive miRNA [27,28]. It targets many oncogenic genes such as disintegrin and metalloprotease 17 (ADAM17) [29], Bcl-w [30], Wnt1 [31] and cyclin G1 (CCNG1) [32]. The significant up regulation of miR-122 in the circulating CD133 cells purified from HCC patients associated with HCV infection may be attributed to that CD133 cells serve as a reservoir for HCV which in turn stimulates the expression of miR-122 in favor of promoting its genome replication and translation [34]. Also, the exogenous expression of miR-122 supports HCV replication and propagation in the non- permissive cell line [35]. Similarly, our previous study reported that miR-122 was significantly up regulated in the serum samples of HCC patients associated with HCV infection when compared to the healthy controls [14]. As for miR-122, miR-192 also enhances HCV replication [36]. Moreover, Yan-Chun et al., reported that miR-192-5p promotes the proliferation and metastasis of HCC expressing CD133 and CD90 cell surface markers through targeting semaphorin 3A (SEMA3A) [37].

Additionally, miR-125a is frequently down-regulated in HCC and it inversely correlated with aggressiveness and poor prognosis of the tumor. Ectopic expression of miR-125a may down-regulate MMP11 and VEGF in vitro and in vivo supporting its role as tumor suppressive miRNA; inhibiting the proliferation, invasion and metastasis of HCC [38]. Moreover, miR-125a inhibits the invasion of HCC cells through regulating the PI3K/AKT/mTOR pathway [39]. However, the significant up-regulation of miR-125a-5p in this study came in agreement with the findings of another study [39].

| miRNA   | Target    | Gene annotation                                                                 |
|---------|-----------|----------------------------------------------------------------------------------|
| miR-122 | Bcl-w     | Inhibits apoptotic pathway                                                       |
|         | ADAM17    | Process many receptors as EGFR, TNFR-1 and TNFR-II Notch receptors. It plays a     |
|         |           | prominent role in notch pathway activation                                         |
|         | Wnt-1     | Reacts with frizzled family receptor results in activation of wnt/β-catenin.       |
|         | CCNG1     | p53 and p73 activate the CCNG1 during the transcription steps that in turn suppress p53 |
|         |           | family proteins leading to cell survival activation.                              |
| miR-192 | SEMA3A    | Inhibits the Rac-PAK pathway responsible for regulation of actin dynamics; resulting in cytoskeleton remodeling. |
| miR-181b | TIMP3     | Exerts its anti-angiogenic effect via a direct interaction with vascular endothelial growth factor (VEGF) receptor-2 resulting in inhibition of proliferation, migration and tube formation of endothelial cells (ECs). |
|         | GATA6     | The transcription factor GATA6 directly regulates expression of leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) involved in the differentiation pathway. |
|         | CDX2      | CDX2 is (caudal type homeobox 2) is an important transcription factor in the differentiation pathway |
|         | NLK       | Inhibits of wnt/β-catenin signaling                                               |
| miR-125a-5p | BAK-1   | Involved in S6K1-BAD-BAK apoptotic pathway                                        |
|         | P53       | Involved in P53 apoptotic pathway                                                |
|         | EBBR2/3   | Involved in cytoskeleton remodeling                                              |

https://doi.org/10.1371/journal.pone.0193709.t003
with an early report by Guo et al. who proved that miR-125a alone was capable of increasing the number of hematopoietic stem cells in vivo via targeting multiple proapoptotic genes e.g. Bak1 [40]. In addition, ERBB2 and ERBB3 were negatively regulated by miR-125a and miR-125b. In CD133+ cells, the down-regulation of ERBB2 due to the effect of miR-125 might lead to more polarized morphology. Therefore, miR-125a plays an anti-apoptotic role and participates in remodeling of cytoskeleton and dedifferentiation [41].

miR-221 is upregulated in 70%–80% of HCC samples with the maximum divergence affecting several cancer pathways [42]. Also, miR-221 stimulates the onset of tumors, promotes tumor progression and shortens the time to death in the mouse model of liver cancer [43].
controls cell cycle progression, apoptosis, cell migration and stemness through targeting \textit{CDKN1B} (p27) and \textit{CDKN1C} (p57), \textit{PUMA}, \textit{FOXO3}, \textit{PTEN}, \textit{Bim}, \textit{c-Kit}, \textit{TIMP3}, \textit{ER-}\textalpha\textit{ and }\textit{DNMT3b} [44–46]. In line with this, over expressing of \textit{miR-221} enhances proliferation, migration, and invasion capability of the HCC cells [42,47,48]. Our previous study reported an up-regulation of \textit{miR-221} in HCC patients` sera compared to LC patients [14]. We have previously reported a similar data regarding the up regulation of \textit{miR-221} in HCC patients` sera compared to LC patients.

https://doi.org/10.1371/journal.pone.0193709.g007

\textbf{Fig 7.} A) Volcano plot representing the differential expression of the 13 miRNAs in CD133+ cells of the control group (BM) versus the control group (PB). B) Volcano plot representing the differential expression of the 13 miRNAs in CD133+ cells of the LC group (BM) versus the LC group (PB). C) Volcano plot representing the differential expression of the 13 miRNAs in CD133+ cells of the LC group (BM) versus the control group (BM). D) Venn graph showing the differential expression of 13 miRNAs of the CD133+ cells of the LC group (PB&BM) compared to the CD133+ of control group (PB & BM) respectively.
On comparing CD133+ cells of the HCC group (PB) to those cells of the control group (PB), miR-122, miR-192, miR-885-5p, miR-224, miR-125a-5p, miR-181b and miR-199a-3p were significantly up-regulated whereas miR-22 was significantly down-regulated. Similarly, Gui et al. reported that miR-122, miR-192, miR-885-5p and miR-224 were up regulated in the sera of HCC and LC patients compared to the normal controls [49]. Moreover, Chen et al. showed that miR-224 starts to be up regulated from the precancerous stage and its up regulation persists throughout the HCC development [50]. miR-224 plays an important role in cell proliferation, migration, invasion, and prevention of apoptosis in HCC through its binding to target genes, such as CDC42, CDH1, PAK2, BCL-2, and MAPK1 suggesting its role as an oncomir [51,52].

Down regulation of miR-199a-3p in HCC has been reported in various previous studies [53–56] supporting its function as a tumor suppressor miRNA. On the contrary, miR-199a-3p

Table 4. The differential expression of the studied miRNAs in the CD133+ cells of the HCC group versus the normal control group.

| No | miR-name  | Fold change | 95% CI        | P value   |
|----|-----------|-------------|---------------|-----------|
| 1  | miR-122   | 1.634       | (1.33–1.93)   | < 0.0001*** |
| 2  | miR-192   | 1.4798      | (1.28–1.69)   | < 0.0001*** |
| 10 | miR-125a-5p | 1.4441   | (1.21–1.67)   | 0.0004**    |
| 11 | miR-181b  | 2.593       | (1.49–2.34)   | < 0.0001*** |

https://doi.org/10.1371/journal.pone.0193709.t004

Fig 8. A) Histogram showing the differential expression of the 13 miRNAs in CD133+ cells of the control group (BM) versus the control group (PB). B) Histogram showing the differential expression of the 13 studied miRNAs in CD133+ cells of the LC group (BM) versus the LC group (PB). C) Histogram showing the differential expression of the 13 miRNAs in CD133+ cells of the LC group (BM) versus the control group (BM). """ miRNA is significant at 0.05 level while """" miRNA is significant at 0.01 level.

https://doi.org/10.1371/journal.pone.0193709.g008
was reported to be upregulated and promote tumor progression in other cancer types [57–60]. It also promotes hematopoietic stem/progenitor cells (HSPC) proliferation and plays a crucial role in hematopoiesis [61].

MiR-22 also plays an important role in tumorigenesis [62]. The significant down regulation of miR-22 was concordant with our previous data which reported its down regulated level in the sera of HCC patients compared to LC patients [14]. Also, Zang et al., reported that the decreased level of miR-22 was associated with poor clinical outcome of liver cancer patients [62]. Several studies addressed that miR-22 over-expression targeting PTEN, p21, and p53 leads to reduction of cell growth, invasion, and metastasis in several cancer types [62–65]; supporting its tumor suppressive function. Furthermore, the proliferation of CD133+ is greatly affected by the miRNA expression level itself. Such relation was reported by Zhang et al. who showed that miR-150 over expression lead to a significant reduction of CD133+ cells, accompanied by significant inhibition of cell growth and tumorsphere formation. So, miR-150 may be involved in liver CSC self-renewal, potentially via modulation of the downstream target c-Myb [66].

Upon comparing CD133+ cells of the HCC group (PB) to CD133+ cells of the CHC group (PB); miR-181b, miR-122, miR-192 and miR-125a-5p were significantly up-regulated. Furthermore, miR-122, miR-192, miR-125a-5p and miR-181b were significantly common up-regulated miRNAs in CD133+ cells of the HCC group (malignant group) compared to the other non-malignant groups (CHC, LC and control groups).

To the best of our knowledge, this the first study showed the differential miRNAs expression pattern of CD133+ cells obtained from BM versus CD133+ cells obtained from PB of the same participant. We found that miR-122, miR-221 and miR-125a-5p were significantly up-
regulated on comparing CD133+ cells separated from BM to those separated from PB of the control group. However, miR-885-5p, miR-224 and miR-199a-3p were significantly up-regulated whereas miR-22, miR-101 and miR-29b were significantly down-regulated in the CD133+ cells separated from BM compared to those separated from PB of the LC group. On comparing the differential miRNAs expression pattern of CD133+ cells separated from BM of the LC group to those separated from BM of the control group vs. CD133+ cells separated from PB of the LC group to those separated from PB of the control group we found that miR-122, miR-192, miR-199a-3p, miR-125a-5p and miR-224 were common significantly down regulated miRNAs. Further study will be needed to investigate the role of those miRNAs in the differentiation of CD133+ cells.

Conclusion

These results have provided the evidence that the miRNAs differentially expressed between the CD133+ cells associated with HCC group associated with HCV infection and CD133+ cells of the other non-malignant studied groups. Those miRNAs are highly involved in stemness, proliferation, and remodeling of cytoskeleton and apoptosis blocking. These findings broaden our knowledge about the molecular characterization along with phenotypic characterization of CD133+ cells for stem cell-based therapies. However, there are some limitations in this study as phenotypic characterization with the double stained and clonogenic assays will be needed to prove the carcinogenic properties of the stem cells harboring CD133+ surface marker in HCC.

Supporting information

S1 Table. The differential expression of the 13 studied miRNAs in the CD133+ cells of the CHC group (PB) versus the control group (PB).

S2 Table. The differential expression of the 13 studied miRNAs in the CD133+ cells of the LC group (PB) versus the control group (PB).

S3 Table. The differential expression of the 13 studied miRNAs in the CD133+ cells of the HCC group (PB) versus the control group (PB).

S4 Table. The differential expression of the 13 studied miRNAs in purified CD133+ cells in HCC group (PB) versus the CHC group (PB).

S5 Table. The differential expression of the 13 studied miRNAs in the CD133+ cells of the HCC group (PB) versus the LC group (PB).

S6 Table. The differential expression of the 13 studied miRNAs in the CD133+ cells of the HCC group (PB) versus all studied non-malignant groups (PB).

S7 Table. The differential expression of the 13 studied miRNAs in the CD133+ cells of the control group (PB) versus the control group (BM).
S8 Table. The differential expression of the 13 studied miRNAs in the CD133+ cells of the LC group (PB) versus the LC group (BM).

S9 Table. The differential expression of the 13 studied miRNAs in the CD133+ cells of the group (BM) versus the control group (BM).

Acknowledgments
This work was supported by Science and Technology Development Fund #5193 to ARNZ and Egypt National Cancer Institute. We also acknowledge Nadia Sayed for her help in histograms drawing by Prism 5 software as well as Yasser Mabrouk Bakr for his advice on the statistical analysis.

Author Contributions
Conceptualization: Abdel-Rahman N. Zekri.
Data curation: Enas Reda El-Sisi, Amira Salah El-Din Youssef.
Formal analysis: Abdel-Rahman N. Zekri, Enas Reda El-Sisi, Amira Salah El-Din Youssef.
Funding acquisition: Abdel-Rahman N. Zekri.
Investigation: Enas Reda El-Sisi, Mahmoud M. Kamel, Ola Sayed Ahmed.
Methodology: Abdel-Rahman N. Zekri.
Resources: Abdel-Rahman N. Zekri, Mohamed El Kassas.
Supervision: Abdel-Rahman N. Zekri, Ahmed Barakat Barakat, Alaa Ismail Abd El-Motaleb.
Validation: Enas Reda El-Sisi.
Visualization: Amira Salah El-Din Youssef.
Writing – original draft: Enas Reda El-Sisi, Amira Salah El-Din Youssef, Auhood Nassar.
Writing – review & editing: Abdel-Rahman N. Zekri, Auhood Nassar, Abeer A. Bahnassy.

References
1. Mittal S, El-Serag HB. Epidemiology of HCC: Consider the Population. J Clin Gastroenterol. 2013; 47: S2–6. https://doi.org/10.1097/MCG.0b013e3182872f29 PMID: 23632345
2. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: Results from a nationwide survey. J Viral Hepat. 2012; 19: 560–7. https://doi.org/10.1111/j.1365-2893.2011.01576.x PMID: 22762140
3. Pang RW, Poon RT. Cancer Stem Cell as a Potential Therapeutic Target in Hepatocellular Carcinoma. Curr Cancer Drug Targets. 2012; 12: 1081–94. PMID: 22873219
4. Rountree CB, Barsky L, Ge S, Zhu J, Senadheera S, Crooks GM. A CD133-expressing murine liver oval cell population with bilineage potential. Stem Cells. 2007; 25: 2419–29. https://doi.org/10.1634/stemcells.2007-0176 PMID: 17585168
5. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007; 120: 1444–50. https://doi.org/10.1002/ijc.22476 PMID: 17205516
6. Hou Y, Zou Q, Ge R, Shen F, Wang Y. The critical role of CD133(+)/CD44(+)/high tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012; 22: 259–72. https://doi.org/10.1038/cr.2011.139 PMID: 21862973
7. Irollo E, Pirozzi G. CD133: To be or not to be, is this the real question? Am J Transl Res. 2013; 5: 563–81. PMID: 24093054
8. Chiba T, Kamiya A, Yokosuka O, Iwama A. Cancer stem cells in hepatocellular carcinoma Recent progress and perspective. Cancer Lett. 2009; 286: 145–53. https://doi.org/10.1016/j.canlet.2009.04.027 PMID: 19464799
9. Bahnassy AA, Zekri AR, El-Bastawisy A, Fawzy A, Shetta M, Hussein N, et al. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease. World J Gastroenterol. 2014; 20: 18240–18248. https://doi.org/10.3748/wjg.v20.i48.18240 PMID: 25561791
10. He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and Suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012; 31: 3357–69. https://doi.org/10.1038/onc.2011.500 PMID: 22056881
11. Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, et al. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene. 2012; 31: 3532–40. https://doi.org/10.1038/onc.2013.478 PMID: 24213572
12. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein1. Cell Stem Cell. 2010; 7(6): 694–707. https://doi.org/10.1016/j.stem.2010.11.010 PMID: 21112564
13. Zekri AR, Youssef AS, Esmat G, Hammad I, Ahmed EA, Ahmed OS, et al. Serum MicroRNAs as differential markers and a molecular therapeutic target for HCV associated liver disease. Hepatology. 2013; 58:410A–411A
14. Zekri AR, Youssef AS, El-Desouky ED, Ahmed OS, Lotfy MM, Nassar AA, et al. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumor Biol. 2016.
15. Ma S. Biology and clinical implications of CD133+ liver cancer stem cells. Exp Cell Res. 2013; 319: 126–32. https://doi.org/10.1016/j.yexcr.2012.09.007 PMID: 22999864
16. Wang ZM, Du WA, Piazza GA, Xi Y. MicroRNAs are involved in the self-renewal and differentiation of cancer stem cells. Acta Pharmacol Sin. 2013; 34: 1374–80. https://doi.org/10.1038/aps.2013.134 PMID: 24122008
17. Qi W, Liang W, Jiang H, Miuyee Waye M. The Function of miRNA in Hepatic Cancer Stem Cell. Biomed Res Int. 2013; 2013.
18. Meng F, Glaser SS, Francis H, Demoros, Passarini JD, Stokes A, et al. Functional Analysis of microRNAs in Human Hepatocellular Cancer Stem Cells. J Cell Mol Med. 2012; 16: 160–73. https://doi.org/10.1111/j.1582-4934.2011.01282.x PMID: 21352471
19. Ji J, Yamashita T, Budhu A, Forgues M, Jia H, Li C, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009; 50: 472–80. https://doi.org/10.1002/hep.22989 PMID: 19585654
20. Yang L, Ma Z, Wang D, Zhao W, Chen L, Wang G. MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biol Ther. 2010; 9: 803–8. PMID: 20364114
21. Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, et al. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget. 2014; 5: 6049–62. https://doi.org/10.18632/oncotarget.2157 PMID: 25153722
22. Li K, Liu C, Zhou B, Bi L, Huang H, Lin T, et al. Role of EZH2 in the Growth of Prostate Cancer Stem Cells Isolated from LNCaP Cells. Int J Mol Sci. 2013; 14: 11981–93. https://doi.org/10.3390/ijms140611981 PMID: 23739676
23. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012; 72: 335–45. https://doi.org/10.1158/0008-5472.CAN-11-2182 PMID: 22108826
24. Nagano T, Higashisaka K, Kunieda A, Iwahara Y, Tanaka K, Nagano K, et al. Liver-specific microRNAs as biomarkers of nanomaterial-induced liver damage. Nanotechnology. 2013; 24: 405102. https://doi.org/10.1088/0957-4484/24/40/405102 PMID: 24029385
25. Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012; 9: 137–42. https://doi.org/10.4161/rna.18827 PMID: 22258222
26. Thakral S, Ghoshal K, miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr Gene Ther. 2015; 15: 142–50. PMID: 25537773
27. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009; 28: 3526–36. https://doi.org/10.1038/onc.2009.211 PMID: 19617899
28. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009; 284: 32015–27. https://doi.org/10.1074/jbc.M109.016774 PMID: 19726678

29. Tsai WC, Hsu PW, Lai TC, Chau CY, Lin CW, Chen CM, et al. MicroRNA-122, a tumor suppressor MicroRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009; 49: 1571–82. https://doi.org/10.1002/hep.22806 PMID: 19296470

30. Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008; 375: 315–20. https://doi.org/10.1016/j.bbrc.2008.07.154 PMID: 18692484

31. Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, et al. MicroRNA -122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int. 2012; 32: 752–60. https://doi.org/10.1111/j.1478-3231.2011.02750.x PMID: 22276989

32. Gramantieri L, Ferracin M, Fornari F, Veronesi A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a MicroRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007; 67: 6092–9. https://doi.org/10.1158/0008-5472.CAN-06-4607 PMID: 17616664

33. Salama H, Zekri A-RN, Bahnassy A a, Medhat E, Halim H a, Ahmed OS, et al. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol. 2010; 16: 5297–5305. https://doi.org/10.3748/wjg.v16.i42.5297 PMID: 21072892

34. Jopling CL. Regulation of hepatitis C virus by microRNA -122. Biochem Soc Trans. 2008; 36: 1220–3. https://doi.org/10.1042/BST0361220 PMID: 19021529

35. Kambara H, Fukuhara T, Shiokawa M, Ono C, Ohara Y, Kamitani W, et al. Establishment of a Novel Permissive Cell Line for the Propagation of Hepatitis C Virus by Expression of MicroRNA miR122. J Virol. 2012; 86: 1382–93. https://doi.org/10.1128/JVI.06242-11 PMID: 22114337

36. Ishida H, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S, et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun. 2011; 412: 92–7. https://doi.org/10.1016/j.bbrc.2011.07.049 PMID: 21802413

37. Yan-Chun L, Hong-Mei Y, Zhi-Hong C, Qing H, Yan-Hong Z, Ji-Fang W. MicroR NA-192-5p Promote the Proliferation and Metastasis of Hepatocellular Carcinoma Cell by Targeting SEMA3A. Appl Immunohistochem Mol Morphol. 2015.

38. Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, et al. Ectopic expression of miR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 2012; 7: e40169. https://doi.org/10.1371/journal.pone.0040169 PMID: 22768249

39. Tang H, Li PR, Liang P, Zhou YL, Wang GW. miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2015; 10: 681–6. https://doi.org/10.3892/ol.2015.3264 PMID: 26622553

40. Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci U S A. 2010; 107: 14229–34. https://doi.org/10.1073/pnas.0913574107 PMID: 20616003

41. Bissels U, Wild S, Tomiuk S, Hafner M, Scheel H, Mihailovic A, et al. Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells. Stem Cells. 2011; 29: 847–57. https://doi.org/10.1002/stem.627 PMID: 21394831

42. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Cahn GA, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008; 27: 5651–61. https://doi.org/10.1038/onc.2008.178 PMID: 18521080

43. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. MiR221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 2010; 107: 264–9. https://doi.org/10.1073/pnas.0913574107 PMID: 20018759

44. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008; 283: 31079–86. https://doi.org/10.1074/jbc.M806041200 PMID: 18790736

45. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G, miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012; 12: 27–33. PMID: 22082479

46. Roscigno G, Quintavalle C, Donnarumma E, Puoti I, Diaz-lagares A, Iaboni M, et al. MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. Oncotarget. 2016; 7: 580–592. https://doi.org/10.18632/oncotarget.9797 PMID: 26556862
47. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 2008; 68: 2773–80. https://doi.org/10.1158/0008-5472.CAN-07-6754 PMID: 18413744

48. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Nagankeu A, et al. miR-221 and 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009; 16: 498–509. https://doi.org/10.1016/j.ccr.2009.10.014 PMID: 19962668

49. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci. 2011; 120: 183–93. https://doi.org/10.1042/CS20100297 PMID: 20815808

50. Chen PJ, Yeh SH, Liu WH, Lin CC, Huang HC, Chen CL, et al. Androgen pathway stimulates MicroRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology. 2012; 56: 632–43. https://doi.org/10.1002/hep.26596 PMID: 22392644

51. Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H, Chayama K. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2013; 28: 565–75. https://doi.org/10.1111/j.1440-1746.2012.07271.x PMID: 22989374

52. Zhang LP, Meng ZQ. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int. 2015; 731781. https://doi.org/10.1155/2015/731781 PMID: 25688365

53. Formari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010; 70: 5184–93. https://doi.org/10.1158/0008-5472.CAN-10-0145 PMID: 20501828

54. Lin L, Lin Y, Jin Y, Zheng C. Microarray analysis of microRNA expression in liver cancer tissues and normal control. Gene. 2013; 523: 158–60. https://doi.org/10.1016/j.gene.2013.02.055 PMID: 23583794

55. Wojcicka A, Swiercik M, Kornasiewicz O, Gierlikowski W, Maciag M, Kolanowska M, et al. Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. Int J Biochem Cell Biol. 2014; 53: 206–17. https://doi.org/10.1016/j.biocel.2014.05.020 PMID: 24875649

56. Yin J, Hou P, Wu Z, Wang T, Nie Y. Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma. Tumour Biol. 2015; 36: 4501–7 https://doi.org/10.1007/s13277-015-3092-0 PMID: 25618599

57. Wang Z, Ma X, Cai Q, Wang X, Yu B, Cai Q, et al. MiR-199a-3p promotes gastric cancer progression by targeting ZHX1. FEBS Lett. 2014; 588: 4504–12. https://doi.org/10.1016/j.febslet.2014.09.047 PMID: 25448600

58. Lunavat TR, Cheng L, Kim DK, Bhadury J, Jang SC, Lasser C, et al. Small RNA deep sequencing illuminates subsets of extracellular vesicles released by melanoma cells—evidence of unique microRNA cargos. RNA Biol. 2015; 12: 810–23 https://doi.org/10.1080/15476286.2015.1056975 PMID: 26176991

59. Veit JA, Schechenbach K, Schuler PJ, Laban S, Wiggenhauser PS, Thierauf J, et al. MicroRNA expression in differentially metastasizing tumors of the head and neck: adenoid cystic versus squamous cell carcinoma. Anticancer Res. 2015; 35: 1271–7. PMID: 25750274

60. Kunility PR, Bojmar L, Tjomsland V, Larsson M, Olofsson C, Ahlgren G., et al. miR-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. Oncotarget. 2016; 7: 16396–408 https://doi.org/10.18632/oncotarget.7651 PMID: 26918939

61. Alemdeh MF, Haanstra JR, de Looper HW, van Strien PM, Verhaegen-Oldemans J, Caljouw Y, et al. ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation. Blood. 2015; 125: 3937–48. https://doi.org/10.1182/blood-2014-11-612507 PMID: 25778535

62. Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 2010; 103: 1215–20. https://doi.org/10.1038/sj.bjc.6605895 PMID: 20842113

63. Li J, Liang S, Yu H, Zhang J, Ma D Lu X. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol. 2010; 119: 543–8. https://doi.org/10.1016/j.ygyno.2010.08.034 PMID: 20869762

64. Li J, Zhang Y, Zhao J, Kong F Chen Y. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem. 2011; 375: 31–8.

65. Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, Fujiwara Y, Nakai M, et al. Tumor suppressor miR-22 determines p53 dependent cellular fate through post-transcriptional regulation of p21. Cancer Res. 2011; 71: 4628–39. https://doi.org/10.1158/0008-5472.CAN-10-2475 PMID: 21965979

66. Zhang J, Luo N, Luo Y, Peng Z, Zhang T, Li S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol. 2012 40 (3):747–56. https://doi.org/10.3892/ijo.2011.1242 PMID: 22025269